- 1 Post-acute sequelae of COVID-19 and adverse psychiatric outcomes: an etiology and risk
- 2 systematic review protocol
- 3 Andem Effiong<sup>1</sup>
- 1. Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada
- 6 Correspondence to: Andem Effiong; andem.effiong@me.com

#### 7 ABSTRACT

- 8 **Introduction** The post-acute sequelae of COVID-19 (PASC) is a syndrome characterized by
- 9 persistent COVID-19 symptoms or the onset of new symptoms following recovery from the
- initial or acute phase of the illness. Such symptoms often occur four or more weeks after being
- diagnosed with COVID-19. Although a lot of work has gone into understanding the long-term
- mental health effects of PASC, many questions related to the etiology and risk of this condition
- 13 remain. Thus, this protocol is for a systematic review assessing the association between PASC
- and adverse psychiatric outcomes and whether people with PASC are at greater risk of
- developing an adverse psychiatric outcome than those without PASC.
- Methods and analysis Various medical databases (e.g., PubMed and EMBASE) will be
- searched for eligible articles using predefined search criteria. Gray literature will also be
- 18 explored. Epidemiological observational studies and secondary analyses of randomized
- controlled trials that report a quantitative relationship between PASC and at least one adverse
- 20 psychiatric outcome will be included. The Population, Exposure of interest, Comparator, and
- 21 Outcome (PECO) framework will be used as a standardized framework for the inclusion criteria.
- The Joanna Briggs Institute (JBI) critical appraisal tools will be used to assess methodological
- 23 quality and critically appraise the risk of bias in included studies. A random-effects meta-
- 24 analysis will be conducted if possible. A formal narrative synthesis will be performed if a meta-
- analysis is impossible due to substantial heterogeneity across studies. The Grading of
- 26 Recommendations Assessment, Development and Evaluation (GRADE) approach will be used to
- 27 rate the cumulative certainty of the evidence for all outcomes.
- 28 **Ethics and Dissemination** Ethical approval is not required for this study. The study results will
- be published in a peer-reviewed journal.

31

32

33

35

36

30 **Prospero registration number** CRD42022308737

- 34 Strengths and limitations of this study
  - This study documents and addresses etiology, risk factors, and long-term symptoms of COVID-19 among people with post-acute sequelae of COVID-19 (PASC).

- It focuses on a key priority area for new evidence syntheses on the clinical management of COVID-19 and pandemic-related conditions.
  - It will include evidence on non-hospitalized and hospitalized patients with a history of PASC.
  - Substantial heterogeneity across studies may limit the ability to perform a meta-analysis.
  - Findings will inform disease prevention, decision-making, healthcare policy, and clinical research.

#### BACKGROUND

### Rationale

37

38 39

40

41 42

43

44

45

46

- Coronavirus disease 2019 (COVID-19) is a contagious illness caused by the severe acute
- respiratory syndrome coronavirus 2 (SARS-CoV-2). Persistent and long-lasting (>4 weeks )
- symptoms following infection with acute COVID-19 have given rise to a syndrome known as
- 51 post-acute sequelae of COVID-19 (PASC) or long COVID.<sup>1, 2, 3</sup> Incidence and prevalence
- estimates for people with COVID-19 presenting with or reporting persistent psychiatric
- symptoms months following initial infection range from 0.8 49% <sup>1,2,3,4,5</sup> Among 44 759 people
- with no recorded history of psychiatric illness, the estimated overall probability of being
- 55 diagnosed with new-onset psychiatric illness in the 90 days following a confirmed diagnosis of
- 56 COVID-19 was 5.8% in a retrospective cohort study. <sup>6</sup> Similarly, clinical anxiety and depression,
- as well as other psychiatric sequelae, have been reported following diagnosis with COVID-19 in
- other studies.<sup>6,7,8</sup> Although sex and age are considered to be sociodemographic risk factors for
- 59 PASC, there is no consensus on other baseline clinical features that act as independent predictors
- of PASC. 9, 10 The prevalence of PASC symptoms is higher in women compared with men. 10.
- Among people aged 35-49 years, the prevalence of PASC is 26.8% compared with 26.1% and
- 62 18% among people aged 50-69 years and 70 years or older, respectively. 10
- 63 Persistent symptoms occur weeks and months after infection irrespective of initial disease
- severity (mild, moderate, severe, critical). <sup>11, 12</sup> Mendez et al. reported in their cross-sectional
- study that two months after discharge, neurocognitive impairment, psychiatric morbidity, and
- poor quality of life were markedly prevalent among 179 COVID-19 survivors who had been
- 67 hospitalized. 12 Nevertheless, Vannorsdall and Oh posit that current research on the post-acute
- 68 phase following hospitalization has been conflicting due to the absence of a detailed,
- standardized neuropsychological evaluation of COVID-19 patients after hospitalization. <sup>13</sup> In
- addition, they stated that literature on PASC and adverse mental health outcomes are mostly
- 71 limited to studies that cannot establish causal relationships or lack generalizability (e.g., case
- 72 reports, case series, and data obtained from cognitive screening instruments). <sup>13</sup> Thus, more high-
- 73 quality studies are warranted.<sup>13</sup>
- In a study where the short-term and long-term sequelae of COVID-19 were systematically
- evaluated, PASC was categorized as short-term (1 month), intermediate-term (2-5 months), and

- 76 long-term (≥ 6 months) following COVID-19 diagnosis. 14 Clinical manifestations of PASC were
- classified into organ systems, i.e., cardiovascular, dermatologic, digestive, ear, nose, and throat;
- mental health, neurologic, and respiratory; constitutional symptoms; and functional mobility.<sup>14</sup>
- 79 The mechanisms leading to the post-acute and chronic neuropsychiatric manifestations of
- 80 COVID-19 may be due to the direct effect of the viral infection and the indirect effect on mental
- 81 health due to social isolation, post-traumatic stress, and job loss. Specifically, correlations have
- been observed between COVID-19 post-traumatic stress scores, general distress, and sleep
- disruption. 14, 15 Despite those correlations, Khubchandani et al. stated that the causal pathways
- and etiology of adverse mental health outcomes in people who were infected with COVID-19 are
- 85 multidimensional and complex. <sup>16</sup>
- To clarify whether COVID-19 is a risk factor for psychiatric disorders and vice-versa, an
- electronic health record network cohort study of 69 million people consisting of 62 354 people
- with a COVID-19 diagnosis compared the rates of psychiatric sequelae of health in the initial
- 89 four months of the pandemic (January April 2020) and subsequently (after April 2020). <sup>17</sup> The
- 90 study found that the rate of all diagnoses of psychiatric disorders and relapses was greater
- 91 following a COVID-19 infection compared with after control health events (e.g., influenza
- 92 infection, skin infection, other respiratory tract infections, and fracture). <sup>17</sup> Similarly, a diagnosis
- of psychiatric disorder in the 12 months preceding the COVID-19 pandemic was associated with
- a 65% increased risk of COVID-19 (relative risk (RR) = 1.65, 95% confidence interval (CI):
- 95 1.59-1.71; p < 0.0001) compared with a matched cohort of people with specific physical risk
- 96 factors for COVID-19 minus a psychiatric diagnosis. <sup>17</sup> Whereas these associations were partly
- 97 attributed to illness severity and pandemic-related contextual factors (e.g., social isolation,
- overwhelmed healthcare systems, and stigma), they do not adequately account for observed
- 99 differences in psychiatric sequelae. <sup>17</sup> Moreover, the inability to conclusively determine why
- there were between twofold and threefold increases in the risk of neurologic and psychiatric
- complications following a COVID-19 infection, in this and other studies, calls for further
- examination of the association between COVID-19 and risk factors for psychiatric morbidity.
- 103 17,18, 19
- With many long-term adverse mental health outcomes linked to COVID-19, effective
- interventions which optimize recovery and minimize relapse are needed. Such interventions may
- serve as appropriate tools to evaluate risk factors that may cause maladaptive psychiatric
- responses. <sup>20</sup> Furthermore, they may aid with the management of anxiety, fear, frustration,
- stigma, and paranoia by mitigating psychopathological symptoms and reducing contextual
- stress.<sup>20</sup> Interventions that have been assessed in COVID-19 patients include virtual and
- physical psychotherapeutic approaches, e.g., cognitive behavioral therapy (CBT), emotional
- freedom techniques (EFT), and ultra-brief psychological interventions (UBPI); combined
- psychiatric and psychological interventions; technology and media; complementary and
- alternative therapies; self-care; spirituality and religion; and pharmacological. 21, 22
- Evidence on the effectiveness of these interventions is mixed and not thoroughly synthesized,
- with quality inadequately assessed in earlier studies and may vary depending on COVID-19
- duration and severity. In a randomized controlled clinical trial of 51 people with COVID-19

consisting of an experimental group receiving progressive muscle relaxation (PMR) technology 117 118 for 30 minutes each day for five consecutive days and a control group receiving only usual care 119 and treatment, subjects in the experimental group reported lower depressive symptoms, lower anxiety levels, and better sleep quality compared with those in the control group. <sup>23</sup> Another 120 randomized control trial of 30 hospitalized patients with COVID-19 assigned to an experimental 121 or control group reported an improvement in all outcome measures among intervention group 122 subjects compared to controls.<sup>24</sup> In that study, a short four-session crisis intervention package 123 tailored to cover COVID-19-specific guidance was delivered by clinical psychologists.<sup>24</sup> Topics 124 covered included tension reduction, relaxation, adjustment, responsibility skills enhancement, 125 and promoting resilience.<sup>24</sup> Outcomes measures in the study were derived from the Depression, 126 Anxiety, and Stress Scale (DASS21), Symptom Checklist 25 (SCL-25), and the abbreviated 127 version of the World Health Organization Quality of Life assessment (WHOQOL-BREF).<sup>24</sup> 128 129 Lack of cultural specificity, methodological issues, small sample sizes, lack of follow-up, unadjusted confounding factors, and brief time spans in both studies limit their 130 generalizability. 23, 24 131 During the COVID-19 pandemic, digital interventions to deliver health care have gained 132 widespread acceptance.<sup>25</sup> Remote care coordination and provision have been adopted to help 133 reduce the risk of disease transmission.<sup>25</sup> Mobile applications have also been used for contact 134 tracing and information dissemination.<sup>25</sup> Although an evidence synthesis of digital interventions 135 to attenuate the adverse effects of the COVID-19 pandemic on public mental health highlighted 136 their importance in mental disorder prevention and mental health promotion; it noted that 137 evidence on their cost-effectiveness, process quality, and long-term outcomes is sparse. <sup>26</sup> 138 Furthermore, the negative impact and risks of the COVID-19 pandemic are sometimes more 139 significant in vulnerable and clinically extremely vulnerable populations (e.g., people over the 140 141 age of 70, pediatric patients with cystic fibrosis, or people with developmental disabilities) who may be digitally disadvantaged. 26, 27, 28 142 Presently, it is unclear what duration of PASC, etiologies and risk factors are most associated 143 with the manifestation or persistence of adverse psychiatric outcomes (e.g., depression, anxiety, 144 substance use disorder, post-traumatic stress disorder, psychosis, dementia, self-harm, suicide) 145 146 compared with other health events. A prospective cohort study of patient-reported outcome measures (PROM) three months after initial COVID-19 symptom onset noted impairment with 147 self-care and anxiety or depression as being present in 13% and 22% of its 78 subjects with at 148 least one Charlson comorbidity at baseline compared to subjects without any Charlson 149 comorbidities (4% and 9% respectively). Among subjects without any Charlson comorbidities, 150 70% reported an abnormal PROM, and 33% had at least one moderate issue in at least one 151 EuroQol- 5 Dimension (EQ-5D).<sup>29</sup> In addition, questions remain about the long-term (( $\geq 6$ 152

Although some studies indicate that most people who acquire COVID-19 are at risk of

months) outcomes of COVID-19. 30

- psychiatric sequelae and their symptoms tend to improve over time, others suggest that
- symptoms may worsen over time or point to a different disease trajectory.<sup>30, 31</sup>Research and any

- future recommendations about PASC and mental health should be guided by the best available
- evidence.
- Few epidemiological studies have investigated the short and long-term impact of COVID-19
- and PASC on mental health. Thus, this study will examine the causes of adverse psychiatric
- outcomes and risk factors in people with PASC. Furthermore, prior studies on this and related
- topics report internal validity and generalizability (external validity) limitations due to evidence
- derived solely from electronic health records, single network, or claims data. Because data on the
- psychiatric sequelae of PASC are conflicting and sparse, it is imperative to systematically
- summarize the evidence and combine the results of various scientific studies. This study aims to
- generate a new hypothesis on causality and provide a more precise estimate of the risk factors
- underlying PASC and adverse psychiatric outcomes.
- An initial search of peer-reviewed and gray literature found no systematic reviews and meta-
- analyses on the topic. This protocol is for a systematic review that assesses the literature on
- 170 PASC duration and risk factors that act as determinants (etiologies) of adverse psychiatric
- 171 outcomes.

173

182

183

184

188

## **Objectives**

- The primary objective of this systematic review is to determine whether people with PASC are
- at greater risk of developing an adverse psychiatric outcome (depression, anxiety, substance use
- disorder, post-traumatic stress disorder, psychosis, dementia, suicide) than those without PASC.
- 177 Secondary review questions include the following:
- Does the association between PASC and an adverse psychiatric outcome vary with age,
- sex, the severity of COVID-19 (mild, moderate, severe, critical), and duration of PASC
- (short-term (1 month), intermediate-term (2-5 months), and long-term (≥ 6 months)
- following COVID-19 diagnosis or hospital discharge)?
  - Is PASC an independent risk factor for an adverse psychiatric outcome?

#### **METHODS**

- This protocol has been drafted following the Preferred Reporting Items for Systematic Reviews
- and Meta-Analyses (PRISMA) guidance for protocols (PRISMA-P).<sup>32</sup> The systematic review
- will explicitly report any amendments and modifications made to this protocol.

# Eligibility criteria

- 189 Study design/characteristics: The review will include observational studies, namely,
- 190 retrospective and prospective longitudinal cohort, case-control, cross-sectional, case series, and
- case reports. Secondary analyses of randomized controlled trials will also be included. Effect
- measures of risk factors, e.g., risk difference, relative risk, odds ratio, and hazard ratio central to
- the primary outcome, will be included. Risk factors predispose people with PASC to an adverse

- 194 psychiatric outcome. Such risk factors are associated with an increased probability of people
- with PASC having a negative mental health outcome. Information on the relationship between
- risk factors and incidence of primary and secondary outcome measures will be included. Studies
- that do not report a quantitative relationship between PASC and at least one adverse psychiatric
- 198 outcome will be excluded.
- 199 COVID-19 diagnosis must have been confirmed through clinical suspicion or with a positive
- 200 nucleic acid amplification test (NAAT), e.g., reverse transcriptase-polymerase chain reaction
- 201 (RT-PCR); antigen test; or serologic test (e.g., rapid serology test (RST) or enzyme-linked
- immunosorbent assay (ELISA)).<sup>33</sup> Studies will be included if subjects were longitudinally
- observed since the initial diagnosis of COVID-19, i.e., during the acute phase or since the time of
- 204 PASC onset (post-acute or chronic phase). A follow-up time of at least one month since the
- 205 COVID-19 diagnosis is required. Primary and secondary outcomes will encompass etiology, risk
- factors, symptom and illness severity, duration of PASC, and adverse events.
- 207 Participants: Studies with adults as subjects (18 years or older) will be included. Pediatric and
- animal studies will not be included. There will be no sex, ethnicity, or race limitations. The
- search dates will range from December 2019 (date of first confirmed case of COVID-19) until
- 210 March 2022 (the anticipated completion date of the review). COVID-19 filters will be used if
- 211 necessary to limit search results to COVID-19 and PASC related articles.
- 212 Exposure:
- 213 Primary measure
- Post-acute sequelae of COVID-19 (PASC), for this review defined as a continuing
- symptomatic illness or the emergence of new symptomatic illness in people with a
- confirmed history of COVID-19 after recovery from the acute phase of illness. PASC
- will be categorized as short-term (1 month), intermediate-term (2-5 months), and long-
- term ( $\geq$  6 months) following COVID-19 diagnosis or hospital discharge.
- 219 Secondary measures
- Severity of COVID-19 (mild (including asymptomatic), moderate, severe, critical)
- 221 *Comparators(controls):*
- 222 Primary measure
- People with a confirmed history of COVID-19 without PASC
- 224 Secondary measures
- Severity of COVID-19 (mild (including asymptomatic), moderate, severe, critical)
- 227 Outcomes:

228 Primary outcome variable

- 229 Adverse psychiatric outcome
- 230 Depression
- 231 Anxiety
- Substance use disorder
- 233 Post-traumatic stress disorder
- 234 Psychosis
- 235 Secondary outcome variable
- 236 Self-harm
- 237 Suicide

239

# Information (evidence) sources and search strategies

- 240 Information, including titles and abstracts extracted from evidence sources, will be initially
- screened against the review questions. Information deemed eligible for inclusion will undergo
- 242 more comprehensive screening. Once an article, study, or review is considered suitable for
- inclusion, it will be placed in the list of included studies. The steps above will be done for each
- information source, after which duplicates will be removed. The study selection process will be
- described in a PRISMA flow diagram and reported in the systematic review.
- AE will develop the search strategy in consultation with a medical research librarian. The
- following databases and evidence sources will be searched: PubMed, Ovid MEDLINE,
- EMBASE, JBI EBP Database, CINAHL Plus, UpToDate, APA PsycInfo, Google Scholar,
- 249 ProQuest Dissertations & Theses Global, Scopus, Web of Science, the University of Toronto
- 250 COVID-19 Data & Statistical Sources, Centre for Addiction and Mental Health (CAMH)
- 251 COVID-19 National Survey Dashboard reports, and COVID-END. Gray literature will also be
- considered where appropriate. Search strategies will be comprehensive and adapted for each
- information source. See Appendix 1 for a sample of the PubMed search strategy.
- The Covidence (Covidence, Melbourne, Australia) or JBI SUMARI software will be used during
- 255 the systematic review process for screening, appraisal of evidence sources, data extraction,
- 256 synthesis, and study completion.

#### **Study selection**

- 258 Information, including titles and abstracts, extracted from information sources will be initially
- screened by AE and a second reviewer against the research questions. Information deemed
- 260 eligible for inclusion will undergo more comprehensive screening. Once an article, study, or
- review is considered suitable for inclusion, it will be placed in the list of included studies. The
- steps above will be done for each information source, after which duplicates will be removed.
- Disagreements on inclusion will be resolved through discussion or arbitration. The study
- selection process will be described in a PRISMA flow diagram and reported in the systematic
- 265 review.

257

266

## **Data extraction and management**

- Data will be extracted on primary and secondary outcome measures following the PRISMA
- 268 guideline for systematic reviews.<sup>35</sup> Outcome and effect size measures (e.g., adjusted and
- unadjusted odds, risk ratios, hazard ratios, standard errors), p-values, and associated 95%
- 270 confidence intervals. RR for subgroups (e.g., age, sex, duration of PASC, COVID-19 severity)
- will be extracted if reported. The following data will also be extracted: authorship, publication
- year, journal name, study design, study location, sample size, baseline characteristics of subjects,
- demographics (age, sex, ethnicity, or race of subjects,'), study population characteristics (e.g.,
- 274 general population, prisoners, healthcare workers), the definition of PASC, duration of PASC,
- comorbidities, other risk factors, duration of follow-up, list of adjusted and unadjusted colliders
- 276 (e.g., hospitalization, occupation, symptom recognition) and list of adjusted and unadjusted
- 277 confounders (e.g., age, sex, nature of exposure, type of intervention), propensity methods.<sup>34</sup> Two
- 278 reviewers will conduct data extraction. Discrepancies in data extraction will be resolved through
- 279 discussion or arbitration.

291

## Risk of bias in individual studies

- The JBI critical appraisal checklist will be used to determine the methodological quality and
- critically appraise the risk of bias for included studies. Assessment will be done at the study and
- outcome level. Information related to a variable (exposure, outcome, covariate),
- 284 misclassification, confounding, participant selection, reverse causation, missing data, study
- power, and generalizability will be appraised. Two reviewers will initially pilot the checklist to
- enhance consistency, mitigate potential issues with mechanistic scoring, and mitigate
- performance bias in the overall risk of bias assessment. Studies that do not adequately report on
- statistical analyses or address confounding, biases (selection, performance, detection, attrition),
- and other biases will be deemed lower quality studies, i.e., when they consistently have 'no,'
- 290 'unclear, and 'not applicable' ratings' across relevant items.

#### Data synthesis

- Summary treatment effects estimated as continuous outcomes will be converted to OR, RR, risk
- 293 difference, and number needed-to-treat (NNT) with a 95% confidence interval (plus the baseline
- risk) for easier interpretation where possible. A random-effects meta-analysis will be conducted
- 295 if possible. Statistical heterogeneity across studies will be explored using Higgins  $I^2$  and
- Cochran's Q statistics. A Cochran's Q test based on a  $\chi 2$  statistic with a p <0.05 and greater than
- the degrees of freedom (df) will indicate heterogeneity. The  $I^2$  statistic will be interpreted as
- follows: 0-40% = minimal heterogeneity; 30-60% = moderate heterogeneity; 50-90% =
- substantial heterogeneity; 75-100% = considerable heterogeneity. If there is substantial
- 300 heterogeneity, subgroup analysis (based on the duration of PASC or COVID-19 severity) will be
- 301 conducted. Subgroup effect sizes (Cohen's *d or* Hedges *g*) and correlations will be assessed and
- 302 compared with unadjusted values to interpret for meaningful effects. Observed effects will be
- considered robust if the effect estimates of the primary outcome remain consistent or there are no
- large differences in the magnitude of effect across subgroups. Subgroup analyses will not be
- performed if there is minimal or moderate heterogeneity. A formal narrative synthesis will be
- performed if meta-analysis is not possible. The reasons for not pooling data (e.g., high statistical,
- methodological, and clinical heterogeneity) will be reported in the review. A methodological

- quality-based sensitivity analysis presented as a summary table will be used to assess the
- 309 robustness of the findings. Authors of included studies with missing information will be
- 310 contacted for clarification. The Grading of Recommendations, Assessment, Development, and
- Evaluations (GRADE) approach will be used to rate the overall certainty of the evidence
- 312 obtained from the study.

### 313 Patient and public involvement

- Input on the review questions and outcomes was informally sought from patients and people who
- had been previously diagnosed with COVID-19 and PASC.

### 316 Ethics and dissemination

- Ethical approval is not required for this study. Study findings will be disseminated via preprints,
- peer-reviewed publications, conference abstracts, posters, plain language summaries,
- 319 presentations, and infographics.
- 320 Ethics statements
- 321 Patient consent for publication
- 322 Not applicable.
- **Contributors:** AE conceived, designed, and drafted the study protocol.
- Funding: This work was supported by the Canadian Institute of Health Research (Grant number:
- NFRFR-2019-00012). The funding body will not have any role in the systematic review (and
- meta-analysis) process.
- 327 **Competing interests:** None declared.
- **Provenance and peer review:** Not commissioned; externally peer-reviewed.

#### 331 REFERENCES

329

- 1. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR,
- Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N. Post-acute COVID-19 syndrome. Nature medicine. 2021 Apr;27(4):601-15.
- 2. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Group WC. A clinical case definition
- of post-COVID-19 condition by a Delphi consensus. The Lancet Infectious Diseases. 2021
- 337 Dec 21.
- 338 3. Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19:
- summary of NICE, SIGN, and RCGP rapid guideline. bmj. 2021 Jan 22;372.
- 4. Postolache TT, Benros ME, Brenner LA. Targetable biological mechanisms implicated in
- emergent psychiatric conditions associated with SARS-CoV-2 infection. JAMA psychiatry.
- 342 2021 Apr 1;78(4):353-4.

- 5. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry. 2021 May 1;8(5):416-27.
- Santomauro DF, Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, Abbafati C,
  Adolph C, Amlag JO, Aravkin AY, Bang-Jensen BL. Global prevalence and burden of
  depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID pandemic. The Lancet. 2021 Nov 6;398(10312):1700-12.
- 7. Fan FC, Zhang SY, Cheng Y. Incidence of psychological illness after coronavirus outbreak: a meta-analysis study. J Epidemiol Community Health. 2021 Feb 23.
- 8. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet Psychiatry. 2021 Feb 1;8(2):130-40.
- Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G,
  David AS. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry. 2020 Jul 1;7(7):611-27.
- 10. Kaseda ET, Levine AJ. Post-traumatic stress disorder: a differential diagnostic consideration for COVID-19 survivors. The Clinical Neuropsychologist. 2020 Nov 16;34(7-8):1498-514.
- 11. Moreno-Pérez O, Merino E, Leon-Ramirez JM, Andres M, Ramos JM, Arenas-Jiménez J,
  Asensio S, Sanchez R, Ruiz-Torregrosa P, Galan I, Scholz A. Post-acute COVID-19
  syndrome. Incidence and risk factors: A Mediterranean cohort study. Journal of Infection.
  2021 Mar 1;82(3):378-83.
- 12. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and management. bmj. 2021 Jul 26;374.
- 13. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, Horn C,
  Vanshylla K, Di Cristanziano V, Osebold L, Roventa M. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet Regional Health-Europe. 2021 Jul 1;6:100122.
- 14. Mendez R, Balanzá-Martínez V, Luperdi SC, Estrada I, Latorre A, González-Jiménez P,
  Feced L, Bouzas L, Yepez K, Ferrando A, Hervas D. Short-term neuropsychiatric outcomes
  and quality of life in COVID-19 survivors. Journal of internal medicine. 2021 Feb 3.
- 15. Vannorsdall T, Oh ES. Post-acute cognitive and mental health outcomes amongst COVID-19
  survivors: early findings and a call for further investigation. Journal of Internal Medicine.
  2021 Sep 1.
- 16. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, Lekoubou A, Oh JS, Ericson JE, Ssentongo P, Chinchilli VM. Short-term and long-term rates of post-acute sequelae of SARS-CoV-2 infection: a systematic review. JAMA network open. 2021 Oct 1;4(10):e2128568-.
- 17. Forte G, Favieri F, Tambelli R, Casagrande M. COVID-19 pandemic in the Italian
  population: validation of a post-traumatic stress disorder questionnaire and prevalence of
  PTSD symptomatology. International Journal of Environmental Research and Public Health.
  2020 Jan;17(11):4151.
- 18. Khubchandani J, Price JH, Sharma S, Webb FJ. COVID-19 Infection Survivors and the Risk
  of Depression and Anxiety Symptoms: A Nationwide Study of Adults in the United States.
  European Journal of Internal Medicine. 2022 Jan 12.

- 19. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet Psychiatry. 2021 Feb 1;8(2):130-40.
- 20. Varatharaj A, Thomas N, Ellul MA, Davies NW, Pollak TA, Tenorio EL, Sultan M, Easton
  A, Breen G, Zandi M, Coles JP. Neurological and neuropsychiatric complications of
  COVID-19 in 153 patients: a UK-wide surveillance study. The Lancet Psychiatry. 2020 Oct
  1:7(10):875-82.
- 21. Pinna P, Grewal P, Hall JP, Tavarez T, Dafer RM, Garg R, Osteraas ND, Pellack DR,
  Asthana A, Fegan K, Patel V. Neurological manifestations and COVID-19: experiences from
  a tertiary care center at the frontline. Journal of the Neurological Sciences. 2020 Aug
  15;415:116969.
- 22. Orrù G, Rebecca C, Gemignani A, Conversano C. Psychological intervention measures
  during the COVID-19 pandemic.
- 23. Biagianti B, Zito S, Fornoni C, Ginex V, Bellani M, Bressi C, Brambilla P. Developing a
  Brief Tele-Psychotherapy Model for COVID-19 Patients and Their Family Members.
- 24. Damiano RF, Di Santi T, Beach S, Pan PM, Lucchetti AL, Smith FA, Forlenza OV,
  Fricchione GL, Miguel EC, Lucchetti G. Mental health interventions following COVID-19
  and other coronavirus infections: a systematic review of current recommendations and meta analysis of randomized controlled trials. Brazilian Journal of Psychiatry. 2021 Apr 12.
  - 25. Liu K, Chen Y, Wu D, Lin R, Wang Z, Pan L. Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19. Complementary therapies in clinical practice. 2020 May 1;39:101132.

408

- 26. Sotoudeh HG, Alavi SS, Akbari Z, Jannatifard F, Artounian V. The effect of brief crisis intervention package on improving quality of life and mental health in patients with COVID-19. Iranian journal of psychiatry. 2020 Jul;15(3):205.
- 27. Islam MN, Islam AN. A systematic review of the digital interventions for fighting COVID-19: the Bangladesh perspective. Ieee Access. 2020 Jun 15;8:114078-87.
- 28. Rauschenberg C, Schick A, Hirjak D, Seidler A, Paetzold I, Apfelbacher C, Riedel-Heller SG, Reininghaus U. Evidence synthesis of digital interventions to mitigate the negative impact of the COVID-19 pandemic on public mental health: rapid meta-review. Journal of medical Internet research. 2021 Mar 10;23(3):e23365.
- 29. Khilnani A, Schulz J, Robinson L. The COVID-19 pandemic: new concerns and connections
  between eHealth and digital inequalities. Journal of Information, Communication and Ethics
  in Society. 2020 Jun 23.
- 30. Gega L, Aboujaoude E. How Digital Technology Mediated the Effects of the COVID-19
  Pandemic on Mental Health: The Good, the Bad, and the Indifferent. Frontiers in Digital
  Health. 2021;3.
- 31. Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome
  measures after COVID-19: a prospective cohort study. European Respiratory Journal. 2020
  Nov 1;56(5).
- 32. Schou TM, Joca S, Wegener G, Bay-Richter C. Psychiatric and neuropsychiatric sequelae of COVID-19–A systematic review. Brain, Behavior, and Immunity. 2021 Oct 1:97:328-48.
- 33. Schwab K, Schwitzer E, Qadir N. Post-Acute Sequelae of COVID-19 Critical Illness. Critical
  Care Clinics. 2022 Jan 10.

- 34. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart
  LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015 Dec;4(1):1-9.
- 35. Caliendo AM, Hanson KE. RELATED PATHWAYS. COVID-19 diagnosis. UpToDate.
  2022 Jan 21.

- 36. Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, Sharp GC, Sterne J,
  Palmer TM, Smith GD, Tilling K. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nature communications. 2020 Nov 12;11(1):1-2.
  - 37. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021 Mar 29;372.